Results 181 to 190 of about 17,587 (206)

Can trichomoniasis cause pharyngitis? A case report

SAGE Open Medical Case Reports, 2016
Objectives: We report on a heterosexual male with sore throat diagnosed as oral Trichomoniasis vaginalis. Methods: A rapid strep test and throat culture were negative.
Folashade Omole, Onameyore Utuama
exaly   +3 more sources

Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis

BJOG: an International Journal of Obstetrics and Gynaecology, 2021
Trichomoniasis commonly affects women of childbearing age and has been linked to several adverse birth outcomes.
Christina A. Muzny, Megan Clare Craig-Kuhn, A T Jones   +2 more
exaly   +2 more sources

Secnidazole for Trichomoniasis in Women and Men

Sexual Medicine Reviews, 2022
INTRODUCTION Secnidazole (SEC), newly FDA-approved for trichomoniasis, is a potent 5-nitroimidazole with selective toxicity against various infections.
Christina A. Muzny, Olivia T Van Gerwen
exaly   +2 more sources

Secnidazole: a treatment for trichomoniasis in adolescents and adults

Expert Review of Anti-Infective Therapy, 2022
Introduction Single-dose 2-g oral secnidazole (SEC), newly approved by the U.S. Food and Drug administration (FDA) for treatment of trichomoniasis, is a potent 5-nitroimidazole with selective toxicity against various micro-organisms.
Christina A. Muzny, Olivia T Van Gerwen
exaly   +2 more sources

Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.

Clinical Infectious Diseases, 2021
Background Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection. We evaluated the efficacy and safety of secnidazole vs placebo in women with trichomoniasis.
Paul Nyirjesy, Leandro Mena, Christina A. Muzny   +2 more
exaly   +2 more sources

Global burden of trichomoniasis: current status, trends, and projections (1990–2021)

Frontiers in Public Health
Objectives Trichomoniasis one of the most neglected sexually transmitted diseases (STDs), imposes a significant global disease burden. This study aims to assess the burden and trends of trichomoniasis from 1990 to 2021 and to project its incidence from ...
Xiaoang Qin, Xingmin Wei
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Trichomoniasis

Infectious Disease Clinics of North America, 2023
Trichomoniasis is the most common nonviral sexually transmitted infection worldwide. It has been associated with a variety of adverse sexual and reproductive health outcomes for both men and women.
O. V. Van Gerwen, Skye Opsteen, K. Graves, C. Muzny   +3 more
semanticscholar   +1 more source

Triosephosphate isomerase as a therapeutic target against trichomoniasis.

Molecular and biochemical parasitology (Print), 2021
Trichomoniasis is the most common non-viral sexually transmitted infection, caused by the protozoan parasite Trichomonas vaginalis, affecting millions of people worldwide.
C. G. Benítez-Cardoza, L. Brieba, R. Arroyo, A. Rojo-Domínguez, J. L. Vique‐Sánchez   +4 more
semanticscholar   +1 more source

The prevalence of trichomoniasis and associated factors among women treated at a university hospital in southern Brazil

PLoS ONE, 2017
Background Trichomoniasis is the most prevalent non-viral sexually transmitted disease (STD) in the world; however, it remains a neglected parasitic disease.
Carla Vitola Gonçalves, Carlos James Scaini, Gabriel Baracy Klafke   +2 more
exaly   +2 more sources

Gellan gum-based hydrogel containing nanocapsules for vaginal indole-3-carbinol delivery in trichomoniasis treatment.

European Journal of Pharmaceutical Sciences, 2020
Trichomonas vaginalis infection is the STI most common worldwide. Indole-3-carbinol (I3C) is a phytochemical presenting promising biological activities.
Bárbara Felin Osmari, L. M. Giuliani, J. B. Reolon, G. Rigo, T. Tasca, L. Cruz   +5 more
semanticscholar   +1 more source